Abstract
Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been made in the long-term outcome of this disease, with the 5-year survival of patients only 30%. This poor prognosis is due to the late presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs. CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CYP1B1 in primary and metastatic ovarian cancer. The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92%), with a strong correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P= 0.005 Spearman’s rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anthoney DA and Kaye SB (1999) Epithelial ovarian cancer. Presc J 39: 65–71
Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer G1, Willemse PH, van der Zee AG and Suurmeijer AJ (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2 and lung resistance associated protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5: 2798–2805
Gonzalez FJ and Gelboin HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: 165–183
Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ and Sutter TR (1996) 17-β-Estradiol hydroxylation catalysed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93: 9776–9781
Iyer L and Ratain MJ (1998) Pharmacogenetics and cancer chemotherapy. Eur J Cancer 34: 1493–1499
Kivisto KT, Kroemer HK and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anti-cancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523–530
Kristensen GB and Tropé C (1997) Epithelial ovarian carcinoma. Lancet 349: 113–117
Le Blanc GA and Waxman DJ (1989) Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metab Rev 20: 395–439
Lorrigan PC, Crosby T and Coleman RE (1996) Current drug treatment guidelines for epithelial ovarian cancer. Drugs 51: 571–584
Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M and Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56: 1296–1302
McFadyen MCE, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT and Murray GI (1999) Immunohistochemical localisation of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47: 1457–1464
McFadyen MCE, McLeod HL, Jackson FC, Melvin WT, Doehmer J and Murray GI (2001) Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anti-cancer drug resistance. Biochemical Pharmacology 62: 207–212
McKay JA, Murray GI, Weaver RJ, Ewen SW, Melvin WT and Burke MD (1993) Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut 34: 1234–1239
McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI and McLeod HL (2000) Expression of cell cycle proteins in primary colerectal tumours does not always predict expression in lymph node matastases. Clin Cancer Res 6: 1113–1118
McLeod HL, McKay JA, Collie-Duguid ESR and Cassidy J (2000) Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer 36: 1706–1712
Murray GI (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 192: 419–426
Murray GI, McKay JA, Weaver RJ, Ewen SW, Melvin WT and Burke MD (1993) Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J Pathol 171: 49–52
Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT and Burke MD (1994) Cytochrome P450 expression in oesophageal cancer. Gut 35: 599–603
Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD and Melvin WT (1997) Tumour specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026–3031
Murray GI, Melvin WT, Greenlee WF and Burke MD (2001) Regulation, function and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297–316
Nelson DR, Koymans L, Kamataki T, Stegman JJ, Feyeteisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalas IC and Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclture. Pharmacogenetics 6: 1–42
Quazi F and McGuire WP (1995) The treatment of epithelial ovarian cancer. CA-A Cancer J Clin 45: 88–101
Rochat B, Morsman JM, Murray GI, Figg WD and McLeod HL (2000) Human CYP1B1 and anti-cancer agent metabolism: mechanism for tumour specific drug interaction?. J Pharmacol Exp Ther 296: 537–541
Shimada T and Guengerich FP (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 4: 391–407
Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27: 256–269
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
McFadyen, M., Cruickshank, M., Miller, I. et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85, 242–246 (2001). https://doi.org/10.1054/bjoc.2001.1907
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1907
Keywords
This article is cited by
-
ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway
Cell Death & Disease (2022)
-
Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers
Scientific Reports (2021)
-
Therapeutic potential of quercetin on human breast cancer in different dimensions
Inflammopharmacology (2020)
-
The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy
Archives of Toxicology (2016)
-
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
Cancer Chemotherapy and Pharmacology (2015)
